Myocardial Inflammation in Cardiac Transthyretin Amyloidosis: Prevalence and Potential Prognostic Implications
Circulation: Heart Failure · 2025-02 · 18 (2)
DOI: 10.1161/circheartfailure.124.012146 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Circulation: Heart Failure, 2025-02. Verfasst von Maximilian Leo Müller und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Angiology and Intensive Care Medicine, Deutsches Herzzentrum der Charité, Berlin, Germany (M.L.M., U.L., B.H., D.M., A.B., …. Hauptthemen laut MEDLINE: Amyloid Neuropathies, Familial, Myocardium, Myocarditis, Heart Failure. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 31 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Despite previous histopathologic evidence for its presence, the role of myocardial inflammation in the development and progression of cardiac transthyretin amyloidosis (ATTR-CA) remains insufficiently understood. Thus, this study sought to characterize the prevalence and potential prognostic implications of myocardial inflammation in ATTR-CA. METHODS: A retrospective observational study including patients with ATTR-CA diagnosed by endomyocardial biopsy was conducted. Myocardial inflammation was diagnosed through a review of routine endomyocardial biopsy reports. Baseline characteristics were compared using the Mann-Whitney U test and the Pearson χ 2 test. Clinical outcomes were monitored via follow-up visits or telephone calls. Primary outcomes were all-cause death and a composite end point of all-cause death or heart failure hospitalization. Kaplan-Meier analyses, as well as univariable and age- and sex-adjusted multivariable Cox regression analyses, were used to assess differences in overall and composite end point-free survival between patients with ATTR-CA with and without myocardial inflammation. RESULTS: A total of 103 patients with ATTR-CA (100 wild type; 3 variant) were enrolled. Median follow-up was 18.2 (8.0–31.1) months. Myocardial inflammation was prevalent in 32% (n=33/103) of patients with ATTR-CA. Among evaluable patients with myocardial inflammation, 96% (n=26/27) and 31% (n=9/29) had elevated CD68 (clusters of differentiation 68)–positive macrophage and CD3 (clusters of differentiation 3)–positive T-cell counts, respectively. Overall survival ( P =0.017) and composite end point-free survival ( P =0.014) were significantly impaired in patients with ATTR-CA with myocardial inflammation (n=33) compared with those without (n=70). Statistical significance for both associations was sustained after adjustment for age and sex, yielding adjusted hazard ratios of 4.72 (95% CI, 1.33–16.71; P =0.016) and 2.30 (95% CI, 1.04–5.11; P =0.041) for all-cause death and the composite end point, respectively. CONCLUSIONS: Our findings affirm previous evidence that myocardial inflammation is present in approximately one-third of all patients with ATTR-CA. Moreover, we provide first data indicating that myocardial inflammation may be associated with a higher risk of death and heart failure hospitalizations in ATTR-CA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardiology, Angiology and Intensive Care Medicine, Deutsches Herzzentrum der Charité, Berlin, Germany (M.L.M., U.L., B.H., D.M., A.B., I.M., S.S.).
- Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität Zu Berlin (M.L.M., A.B., I.M., S.S., D.M., K.H., M.V., U.L., B.H.).
- Amyloidosis Center Charité Berlin, Charité-Universitätsmedizin Berlin, Germany (M.L.M., A.B., I.M., S.S., D.M., K.H., B.H.).
- DZHK (German Centre for Cardiovascular Research), Partner Site Berlin, Germany (A.B., I.M., S.S., D.M., U.L.).
- Berlin Institute of Health at Charité, Germany (I.M., K.H., B.H.).
- Medical Department of Cardiology, Rhythmology, and Angiology, Medical University Lausitz-Carl Thiem, Cottbus, Germany (D.M.).
ORCID-Profile: Maximilian Leo Müller, Anna Brand, Isabel Mattig, Sebastian Spethmann, Daniel Messroghli, Katrin Hahn, Michele Violano, Joshua D Mitchell, Andrea Frustaci, Karin Klingel, Thomas F Lüscher, Ulf Landmesser, Bettina Heidecker
Zitieren
APA
Müller, M. L., Brand, A., Mattig, I., Spethmann, S., Messroghli, D., Hahn, K., Violano, M., Mitchell, J. D., Hare, J. M., Frustaci, A., Klingel, K., Lüscher, T. F., Landmesser, U., & Heidecker, B. (2025). Myocardial Inflammation in Cardiac Transthyretin Amyloidosis: Prevalence and Potential Prognostic Implications. Circulation: Heart Failure, 18(2). https://doi.org/10.1161/circheartfailure.124.012146
Vancouver
Müller ML, Brand A, Mattig I, Spethmann S, Messroghli D, Hahn K, et al. Myocardial Inflammation in Cardiac Transthyretin Amyloidosis: Prevalence and Potential Prognostic Implications. Circulation: Heart Failure. 2025;18(2). doi:10.1161/circheartfailure.124.012146
BibTeX
@article{Mller2025,
author = {Müller, Maximilian Leo and Brand, Anna and Mattig, Isabel and Spethmann, Sebastian and Messroghli, Daniel and Hahn, Katrin and Violano, Michele and Mitchell, Joshua D and Hare, Joshua M and Frustaci, Andrea and Klingel, Karin and Lüscher, Thomas F and Landmesser, Ulf and Heidecker, Bettina},
title = {Myocardial Inflammation in Cardiac Transthyretin Amyloidosis: Prevalence and Potential Prognostic Implications},
journal = {Circulation: Heart Failure},
year = {2025},
volume = {18},
number = {2},
doi = {10.1161/circheartfailure.124.012146}
}
EUVIMED